Manejo de pacientes con infección crónica por el virus de la hepatitis B

Referencias

15. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756–62.
29. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–86.


76. Gish RG, Chang TT, de Man RA, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). Hepatology 2005; 42 (suppl 1):267A (abstr).


94. Poordad F, Dieterich DT, Min AD, et al. Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg(–) chronic hepatitis B patients (Study ETV-027). Gastroenterology 2006; 130 (suppl 2): A848 (abstr).


97. Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos N. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006; 44 (suppl 1): 231A–232A (abstr).


117. Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Klesczewski K, Tenney D. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006; 44 (suppl 1): 229A–30A (abstr).


Sherman M, Martin P, Lee WM, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). Gastroenterology 2006; 130 (suppl 2): A765 (abstr).


